Larimar Therapeutics (LRMR)
(Delayed Data from NSDQ)
$7.35 USD
+0.46 (6.68%)
Updated May 1, 2024 04:00 PM ET
After-Market: $7.35 0.00 (0.00%) 7:58 PM ET
3-Hold of 5 3
D Value D Growth F Momentum F VGM
Income Statements
Fiscal Year end for Larimar Therapeutics, Inc falls in the month of December .
All items in Millions except EPS data.
12/31/23 | 12/31/22 | 12/31/21 | 12/31/20 | 12/31/19 | |
---|---|---|---|---|---|
Sales | 0 | 0 | 0 | 0 | 0 |
Cost Of Goods | 0 | 0 | 0 | 0 | 0 |
Gross Profit | 0 | 0 | 0 | 0 | 0 |
Selling & Adminstrative & Depr. & Amort Expenses | 42 | 37 | 50 | 43 | 46 |
Income After Depreciation & Amortization | -42 | -37 | -50 | -43 | -46 |
Non-Operating Income | 5 | 1 | 0 | 0 | 2 |
Interest Expense | 0 | 0 | 0 | 0 | 2 |
Pretax Income | -37 | -35 | -51 | -42 | -45 |
Income Taxes | 0 | 0 | 0 | 0 | 0 |
Minority Interest | 0 | 0 | 0 | 0 | 0 |
Investment Gains/Losses | 0 | 0 | 0 | 0 | 0 |
Other Income/Charges | 0 | 0 | 0 | 0 | 0 |
Income From Cont. Operations | -37 | -35 | -51 | -42 | -45 |
Extras & Discontinued Operations | 0 | 0 | 0 | 0 | 0 |
Net Income (GAAP) | -37 | -35 | -51 | -42 | -45 |
Depreciation Footnote | 12/31/23 | 12/31/22 | 12/31/21 | 12/31/20 | 12/31/19 |
---|---|---|---|---|---|
Income Before Depreciation & Amortization | -43 | -37 | -50 | -43 | -46 |
Depreciation & Amortization (Cash Flow) | -2 | 0 | 0 | 0 | -1 |
Income After Depreciation & Amortization | -42 | -37 | -50 | -43 | -46 |
Earnings Per Share Data | 12/31/23 | 12/31/22 | 12/31/21 | 12/31/20 | 12/31/19 |
---|---|---|---|---|---|
Average Shares | 43.90 | 25.76 | 17.16 | 11.88 | 3.11 |
Diluted EPS Before Non-Recurring Items | -0.84 | -1.37 | -2.95 | -3.57 | -12.85 |
Diluted Net EPS (GAAP) | -0.84 | -1.37 | -2.95 | -3.57 | -14.65 |
Fiscal Year end for Larimar Therapeutics, Inc falls in the month of December .
All items in Millions except EPS data.
3/31/24 | 12/31/23 | 9/30/23 | 6/30/23 | 3/31/23 | |
---|---|---|---|---|---|
Sales | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Cost Of Goods | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Gross Profit | NA | 0.00 | 0.00 | 0.00 | 0.00 |
SG&A, R&D, and Dept/Amort Expenses | 0.00 | 14.16 | 10.34 | 9.63 | 7.64 |
Income After SG&A, R&D, and Dept/Amort Expenses | 0.00 | -14.16 | -10.34 | -9.63 | -7.64 |
Non-Operating Income | NA | 1.17 | 1.28 | 1.25 | 1.11 |
Interest Expense | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Pretax Income | NA | -12.99 | -9.06 | -8.37 | -6.53 |
Income Taxes | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Minority Interest | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Investment Gains/Losses | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Other Income/Charges | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Income From Cont. Operations | NA | -12.99 | -9.06 | -8.37 | -6.53 |
Extras & Discontinued Operations | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Net Income (GAAP) | NA | -12.99 | -9.06 | -8.37 | -6.53 |
Earnings Per Share Data | 3/31/24 | 12/31/23 | 9/30/23 | 6/30/23 | 3/31/23 |
---|---|---|---|---|---|
Average Shares | NA | 43.91 | 43.90 | 43.90 | 43.90 |
Diluted EPS Before Non-Recurring Items | NA | -0.30 | -0.21 | -0.19 | -0.15 |
Diluted Net EPS (GAAP) | NA | -0.29 | -0.21 | -0.19 | -0.15 |